Established in 1984, Aarti Drugs Limited is a prominent player in the realm of specialty chemicals and bulk drugs manufacturing.
The company boasts an extensive repertoire of over 40 products, encompassing bulk actives, pivotal intermediates, and specialty chemicals. These offerings span a wide array of therapeutic categories, including antibiotics, anti-protozoals, anti-inflammatories, anti-fungals, anti-diabetics, cardio-protectants, vitamins, anti-arthritis agents, and sedatives. These therapeutic groups effectively address both life-saving and lifestyle-associated medical conditions.
Aarti Drugs operates from a robust infrastructure of nine manufacturing units situated in Tarapur, Maharashtra, and an additional two units located in Sarigam, Gujarat. A significant portion of these facilities has been accredited with GMP certification, signifying adherence to stringent quality standards. The company’s global footprint is further underscored by its exports to over 100 countries across the globe.
A testament to its commitment to quality and excellence, Aarti Drugs has secured approvals from esteemed regulatory authorities such as WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS. This recognition underscores the company’s unwavering dedication to maintaining the highest standards in its operations and products.
Aarti Drugs Ltd. Stock Quote #
- Open: ₹576.85
- High – Low: ₹594.00 – ₹571.55
- Previous Close: ₹574.20
- Total Traded Value: 4,29,170
- 52 Weeks High: ₹645.75 (Jul 25, 2023)
- 52 Weeks Low: ₹313.90 (Mar 20, 2023)
- Updated On: Aug 10, 2023 4:00 PM
Aarti Drugs Buyback 2023 Detail #
| Issue Period | Aug 9, 2023 – Aug 17, 2023 |
| Security Name | Aarti Drugs Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 665,000.00 |
| Issue Size (Amount) | ₹59.85 Crores |
| Buyback Price | ₹900 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
Aarti Drugs Buyback 2023 Issue Timetable #
| Last Date to buy shares | Aug 3, 2023 |
| Record Date | Aug 4, 2023 |
| Offer Opens On | Aug 9, 2023 |
| Last Date for receipt of Tender Forms | Aug 17, 2023 |
| Offer Closes On * | Aug 17, 2023 |
| Finalisation of Buyback Acceptance | Aug 23, 2023 |
| Last Date for settlment of bids | Aug 24, 2023 |
| Last Date for Extinguishment of Shares | Sep 4, 2023 |
Buyback Ratio #
| Category | Entitlement Ratio of Buyback | Shares Offered |
|---|---|---|
| Reserved Category for Small Shareholders | 2 Equity Shares out of every 157 Fully paid-up Equity Shares held on the Record Date. | 99,750.00 |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 150 Fully paid-up Equity Shares held on the Record Date. | 565,250.00 |
Company Financials #
| Period Ended | 31 Mar 2019 | 31 Mar 2020 | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 1,455.49 | 1,576.50 | 1,766.01 | 2,207.96 | 2,421.40 |
| Revenue | 1,436.09 | 1,626.75 | 2,159.31 | 2,499.96 | 2,718.25 |
| Profit After Tax | 89.75 | 141.40 | 280.40 | 205.00 | 166.36 |
| Net Worth | 904.27 | 1,026.52 | 1,184.10 | ||
| Reserves and Surplus | |||||
| Total Borrowing |
Stock price at BSE (in preceding 3 months) #
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jun-2023 | 492.95 | 437.35 | 460.04 |
| May-2023 | 478.25 | 423.00 | 452.48 |
| Apr-2023 | 436.00 | 336.05 | 407.57 |
Stock price at NSE (in preceding 3 months) #
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jun-2023 | 493.00 | 439.10 | 459.93 |
| May-2023 | 478.00 | 422.85 | 452.23 |
| Apr-2023 | 436.00 | 336.00 | 407.91 |
Necessity of the Issue #
The Buy Back is being proposed by the Company to fulfill the following objectives:
- The Buyback will help the company to return surplus cash to its shareholders holding Equity Shares.
- The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by a reduction in the equity base, thereby leading to a long-term increase in shareholders value.
- The Buyback gives an option to the shareholders holding Equity Shares of the company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment.
- The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would get classified as Small Shareholders.
Aarti Drugs Buyback 2023 Documents #
Company Contact Information #
Plot No. – N-198,
MIDC, Tarapur,
Tal – Palghar, Dist. Palghar – 401506Phone: +91 22 2401 9025
Email: admin@aartidrugs.com
Website: https://www.aartidrugs.co.in/
Aarti Drugs Buyback 2023 Registrar #
- Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083Phone: +91-22-4918 6270
Email: aartidrugs.buyback2023@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Aarti Drugs Buyback 2023 Manager #
Lead Manager(s)
Registered Broker
- Ghalla Bhansali Stock Brokers Private Limited
Email: pareshv@ghallabhansali.com
